<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24232" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Levonorgestrel</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vrettakos</surname>
            <given-names>Christina</given-names>
          </name>
          <aff>Ross University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bajaj</surname>
            <given-names>Tushar</given-names>
          </name>
          <aff>University of Chicago</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Christina Vrettakos declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tushar Bajaj declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24232.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Levonorgestrel, also known as the morning-after pill, is a first-line oral emergency contraceptive pill with approval from the World Health Organization to prevent pregnancy. It is FDA-approved to be used within 72 hours of unprotected sexual intercourse or when a presumed contraceptive failure has occurred. There have been cases of off-label efficacy for up to 96 hours. This activity covers levonorgestrel, including mechanism of action, pharmacology, adverse event profiles, eligible patient populations, and monitoring, and highlights the role of the interprofessional team in the management of conditions where levonorgestrel therapy is helpful.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the mechanism of action of levonorgestrel.</p></list-item><list-item><p>Review the effective and correct administration of levonorgestrel for morning-after birth control.</p></list-item><list-item><p>Describe the contraindications for using levonorgestrel.</p></list-item><list-item><p>Explain the importance of collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients receiving treatment with levonorgestrel.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24232&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24232">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24232.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Levonorgestrel, also known as the morning-after pill, is a first-line oral emergency contraceptive pill with approval from the World Health Organization to prevent pregnancy. It is FDA-approved to be used within 72 hours of unprotected sexual intercourse or when a presumed contraceptive failure has occurred. There have been cases of off-label efficacy for up to 96 hours.<xref ref-type="bibr" rid="article-24232.r1">[1]</xref> A prescription is not needed, and it is available over the counter at local pharmacies. The FDA has also approved levonorgestrel availability for all age groups due to its lack of life-threatening contraindications and side-effect profile.<xref ref-type="bibr" rid="article-24232.r2">[2]</xref> Levonorgestrel can be used as an oral combination pill with estradiol as a long-term option for birth control and is available in other forms, such as implants or transdermal patches. There is a levonorgestrel-releasing intrauterine device considered to be a &#x0201c;low maintenance&#x0201d; birth control option for women that is efficacious for up to five years.<xref ref-type="bibr" rid="article-24232.r3">[3]</xref> It has also been used off-label effects to treat endometrial hyperplasia, menorrhagia, endometriosis, and menopausal hormone therapy.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-24232.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Levonorgestrel (LNG&#x02014;17alpha-ethynyl-18-methylestr-4-en-17beta-ol-3-one) is a second-generation synthetic progestogen that is the active component of the racemic mixture of norgestrel. It binds to progesterone and androgen receptors, which can delay the release of gonadotropin-releasing hormone from the hypothalamus. This action blunts the luteinizing hormone surge that occurs during the pre-ovulation stage. Ultimately, it can delay or inhibit ovulation by preventing fertilization via inhibiting follicular rupture and releasing a viable egg from the ovaries. Optimal efficacy is also achievable when it is taken in the pre-ovulation stage. Levonorgestrel also induces the thickening of cervical mucus, which helps by interfering with sperm motility and passage. There has been no evidence in recent studies that levonorgestrel significantly affects the endometrium to alter it to prevent pregnancy.<xref ref-type="bibr" rid="article-24232.r4">[4]</xref></p>
        <p>Studies have shown that levonorgestrel is not subject to significant first-pass metabolism. Levonorgestrel undergoes metabolism via hydroxylation, conjugation, and reduction in the liver. Its bioavailability varies from 85% to 100%.<xref ref-type="bibr" rid="article-24232.r5">[5]</xref></p>
      </sec>
      <sec id="article-24232.s4" sec-type="Administration">
        <title>Administration</title>
        <p>For emergency contraceptive use, the recommended dose is 1.5 mg oral tablet within 72 hours. &#x000a0;If&#x000a0;taken within 72 hours after unprotected sex, levonorgestrel can reduce the risk of pregnancy by&#x000a0;up to 87%. If taken within 24 hours, the efficacy is higher. There is also a 0.75 mg oral tablet that can be given with a second 0.75 mg dose if needed 24 hours later. A 3 mg oral levonorgestrel is for patients concomitantly taking a CYP3A4 cytochrome p450 liver enzyme-inducing drug, eg, rifampicin, St. John&#x02019;s wort, carbamazepine, or phenobarbital due to these agents increasing hepatic clearance of levonorgestrel. Vomiting can occur within two hours of administration, at which case the patient would need to repeat the initial dose taken.<xref ref-type="bibr" rid="article-24232.r6">[6]</xref></p>
        <p>For long-term birth control options, the levonorgestrel intrauterine T-shaped device has 52 mg of levonorgestrel covered by a rate-controlling membrane that regulates the rate of release of hormones.<xref ref-type="bibr" rid="article-24232.r3">[3]</xref> The combined oral contraceptive pill with ethinylestradiol comes in a 21-pill pack per month with 0.1 mg of levonorgestrel and 0.02 mg of ethinylestradiol.</p>
      </sec>
      <sec id="article-24232.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>For the emergency contraceptive, the timing of when patients ingest the drug plays a significant role in its efficacy in preventing pregnancy; this means the adverse effect of pregnancy occurring becomes greater when the patient waits over 48 to 72 hours or longer to take the drug as well as taking the medication during an ovulation cycle. Many studies have shown an efficacy reduction in women whose BMI is greater than 30 kg/m<sup>2</sup>, but not significant enough to restrict this subset of patients from using levonorgestrel, which appears to be due to the lower bioavailability of a standard 1.5 mg dose given of levonorgestrel, free plus albumin-bound, in these patients. The most common side effects are menstrual abnormalities, amenorrhea, dysmenorrhea, oligomenorrhea, headaches, and acne. Other side effects that can occur are nausea and vomiting. Importantly, this drug does not protect any patient from sexually transmitted infections and diseases, and the advice to patients is to use condoms for protection.<xref ref-type="bibr" rid="article-24232.r7">[7]</xref><xref ref-type="bibr" rid="article-24232.r8">[8]</xref></p>
        <p>For the intrauterine device, 0.1% of pregnancy occurs within the first year of use. The intrauterine device most commonly causes menstrual irregularities, including amenorrhea and oligomenorrhea. Other side effects of the intrauterine device are similar to those of the combined oral contraceptive pill route, such as ovarian cysts, weight gain, depression, acne, and low libido.<xref ref-type="bibr" rid="article-24232.r3">[3]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>The following may diminish the therapeutic effect of progestins: acitretin, anticoagulants, antidiabetic agents, barbiturates, carbamazepine, fosphenytoin, griseofulvin, mifepristone, phenytoin, primidone, retinoic acid derivatives, and St. John's wort.</p>
        <p>The following may decrease the serum concentration of progestins: aprepitant, artemether, bexarotene, bile acid sequestrants, bosentan, brigatinib, clobazam, CYP3A4 inducers, dabrafenib, darunavir, efavirenz, encorafenib, eslicarbazepine, exenatide, felbamate, fosaprepitant,&#x000a0; ixazomib, lamotrigine, lesinurad, lixisenatide, lopinavir, lorlatinib, lumacaftor, metreleptin, mycophenolate, nelfinavir, nevirapine, oxcarbazepine, perampanel, rifamycin derivatives, saquinavir, sugammadex, and topiramate.</p>
        <p>The following may increase the serum concentration of progestins: atazanavir, cobicistat, tipranavir, and voriconazole.&#x000a0;</p>
        <p>The following may enhance the thrombogenic effect of progestins: C1-inhibitors and carfilzomib.</p>
      </sec>
      <sec id="article-24232.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are several contraindications for the emergency contraceptive form, including allergy, hypersensitivity, severe liver disease, pregnancy, and drug-drug interactions with liver enzyme-inducing drugs.<xref ref-type="bibr" rid="article-24232.r9">[9]</xref></p>
        <p>For the intrauterine device, the contraindications include uterine anomalies (fibroids, cysts), breast carcinoma, active cervicitis/vaginitis, suspected cervical dysplasia, and pregnancy.<xref ref-type="bibr" rid="article-24232.r3">[3]</xref></p>
        <p>Emergency contraceptive form: The medication is not for use in women confirmed to be pregnant; however, there is no proof nor reports of adverse effects on the mother or fetus following inadvertent exposure during pregnancy.<xref ref-type="bibr" rid="article-24232.r10">[10]</xref></p>
        <p>Pregnancy for the IUD: Use during pregnancy or suspected pregnancy is contraindicated.&#x000a0;</p>
        <p>Combined ethinylestradiol and levonorgestrel is pregnancy category X.&#x000a0;</p>
        <p>Breastfeeding: levonorgestrel is present in breast milk; however, the relative infant dose is 8%. Breastfeeding is acceptable when the relative infant dose of a medication is less than 10%.<xref ref-type="bibr" rid="article-24232.r11">[11]</xref></p>
      </sec>
      <sec id="article-24232.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Routine examinations with a gynecologist are encouraged for the long-term combined oral pill or intrauterine device birth control options to monitor side effects and possible pregnancy. Levonorgestrel undergoes metabolism by the liver and is subject to impairment in patients with liver dysfunction. Therefore, monitoring liver function tests at the time of administration may be beneficial. Also, drugs containing CYP3A4 cytochrome p450 liver-enzyme inducing properties require close vigilance when a patient takes levonorgestrel. Patients may need to consider another emergency contraceptive method to avoid drug-drug interactions. These liver-enzyme-inducing drugs can cause rapid metabolism and decrease the efficacy of levonorgestrel when there is concomitant use.<xref ref-type="bibr" rid="article-24232.r12">[12]</xref></p>
      </sec>
      <sec id="article-24232.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There is a lack of research regarding the toxic levels and effects in humans. While there could be toxicity seen in patients with liver disease, there is not enough research to support this. More human trial studies will be necessary. There have been studies that show LD50 to be over 5000 mg/kg in rats when given orally, with a significant decrease in white blood cell counts.<xref ref-type="bibr" rid="article-24232.r13">[13]</xref></p>
      </sec>
      <sec id="article-24232.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>While levonorgestrel is a first-line emergency contraceptive for unwanted pregnancy, communication and teamwork between primary care physicians, gynecologists, obstetricians, pharmacists, nurse practitioners, physician&#x000a0;assistants, and nursing staff working together in an interprofessional team approach to care can make a tangible difference in a patient&#x02019;s experience while taking levonorgestrel. There has been controversy about the morning-after pill being available without a prescription and sold over the counter at any local pharmacy. This agent can be deemed a drug that promotes risky sexual behavior and can also be a drug of convenience for both perceived and verifiable contraceptive failures. This issue is how healthcare teams can combine patient education with adequate treatment plans to promote levonorgestrel use in the most effective way without compromising patient safety.<xref ref-type="bibr" rid="article-24232.r14">[14]</xref> [Level 5]</p>
        <list list-type="bullet">
          <list-item>
            <p>Primary care physicians and gynecologists should routinely ask the patient about pertinent sexual history to help monitor sexual behavior and document changes.</p>
          </list-item>
          <list-item>
            <p>Maintenance of a strong physician-patient relationship so that the patients trust the physicians and can be open and honest about their sexual practices and potentially risky behavior in a judgment-free atmosphere.</p>
          </list-item>
          <list-item>
            <p>Pharmacists should emphasize the side effects of levonorgestrel, its strict timeline to achieve optimal drug efficacy, and how it will not prevent sexually transmitted infections and diseases.</p>
          </list-item>
        </list>
        <p>These examples of interprofessional strategies can optimize the benefits of therapy with levonorgestrel. [Level 5]</p>
      </sec>
      <sec id="article-24232.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24232&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24232">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24232/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24232">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24232.s11">
        <title>References</title>
        <ref id="article-24232.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Chao</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <source>Ulipristal versus Levonorgestrel for Emergency Contraception: A Review of Comparative Clinical Effectiveness and Guidelines [Internet]</source>
            <publisher-name>Canadian Agency for Drugs and Technologies in Health</publisher-name>
            <publisher-loc>Ottawa (ON)</publisher-loc>
            <year>2018</year>
            <month>11</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">30883064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24232.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>David</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berends</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bartley</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Current Opinion of Obstetricians on the Prescription of Emergency Contraception: A German-American Comparison.</article-title>
            <source>Geburtshilfe Frauenheilkd</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>72</volume>
            <issue>11</issue>
            <fpage>1004</fpage>
            <page-range>1004-1008</page-range>
            <pub-id pub-id-type="pmid">25258456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24232.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beatty</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>The levonorgestrel-releasing intrauterine system: Safety, efficacy, and patient acceptability.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>561</fpage>
            <page-range>561-74</page-range>
            <pub-id pub-id-type="pmid">19707273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24232.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahlenborn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Peck</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Severs</surname>
                <given-names>WB</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of action of levonorgestrel emergency contraception.</article-title>
            <source>Linacre Q</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>82</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-33</page-range>
            <pub-id pub-id-type="pmid">25698840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24232.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Basaraba</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Westhoff</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Pike</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Nandakumar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cremers</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Estimating systemic exposure to levonorgestrel from an oral contraceptive.</article-title>
            <source>Contraception</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>95</volume>
            <issue>4</issue>
            <fpage>398</fpage>
            <page-range>398-404</page-range>
            <pub-id pub-id-type="pmid">28041990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24232.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Black</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Hussainy</surname>
                <given-names>SY</given-names>
              </name>
            </person-group>
            <article-title>Emergency contraception: Oral and intrauterine options.</article-title>
            <source>Aust Fam Physician</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>46</volume>
            <issue>10</issue>
            <fpage>722</fpage>
            <page-range>722-726</page-range>
            <pub-id pub-id-type="pmid">29036770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24232.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Festin</surname>
                <given-names>MPR</given-names>
              </name>
              <name>
                <surname>Peregoudov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Seuc</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kiarie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Temmerman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effect of BMI and body weight on pregnancy rates with LNG as emergency contraception: analysis of four WHO HRP studies.</article-title>
            <source>Contraception</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>95</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <page-range>50-54</page-range>
            <pub-id pub-id-type="pmid">27527670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24232.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Che</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Showell</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Interventions for emergency contraception.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2019</year>
            <month>Jan</month>
            <day>20</day>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>CD001324</fpage>
            <pub-id pub-id-type="pmid">30661244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24232.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Back</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Orme</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic drug interactions with oral contraceptives.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1990</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>472</fpage>
            <page-range>472-84</page-range>
            <pub-id pub-id-type="pmid">2191822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24232.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curtis</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Jatlaoui</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Berry-Bibee</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Horton</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Zapata</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Pagano</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Jamieson</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Whiteman</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2016</year>
            <month>Jul</month>
            <day>29</day>
            <volume>65</volume>
            <issue>3</issue>
            <fpage>1</fpage>
            <page-range>1-103</page-range>
            <pub-id pub-id-type="pmid">27467196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24232.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ito</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Drug therapy for breast-feeding women.</article-title>
            <source>N Engl J Med</source>
            <year>2000</year>
            <month>Jul</month>
            <day>13</day>
            <volume>343</volume>
            <issue>2</issue>
            <fpage>118</fpage>
            <page-range>118-26</page-range>
            <pub-id pub-id-type="pmid">10891521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24232.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coricovac</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Farcas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nica</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pinzaru</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Simu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stoian</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Soica</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Proks</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Avram</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Navolan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dumitru</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Popovici</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Dehelean</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Ethinylestradiol and Levonorgestrel as Active Agents in Normal Skin, and Pathological Conditions Induced by UVB Exposure: In Vitro and In Ovo Assessments.</article-title>
            <source>Int J Mol Sci</source>
            <year>2018</year>
            <month>Nov</month>
            <day>14</day>
            <volume>19</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">30441863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24232.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Yi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Oral toxicity of isotretinoin, misoprostol, methotrexate, mifepristone and levonorgestrel as pregnancy category X medications in female mice.</article-title>
            <source>Exp Ther Med</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>853</fpage>
            <page-range>853-859</page-range>
            <pub-id pub-id-type="pmid">25667641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24232.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brand&#x000e3;o</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>[Long-acting reversible contraception methods in the Brazilian Unified National Health System: the debate on women's (in)discipline].</article-title>
            <source>Cien Saude Colet</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>875</fpage>
            <page-range>875-879</page-range>
            <pub-id pub-id-type="pmid">30892508</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
